Are you looking for ASX shares to buy after recent market weakness?
Well, if you are, let's see what analysts are saying about the popular shares in this article, courtesy of The Bull.
Are they buys, holds, or sells? Let's find out:
CSL Ltd (ASX: CSL)
This biotechnology giant's shares have fallen heavily over the past 12 months, but Morgans isn't in a rush to buy them.
This week, the broker has put a hold rating on CSL shares. It appears to be waiting for its performance to improve before recommending it as a buy. It said:
This biotechnology giant has a strong research and development pipeline and a successful track record in launching new products. Its first half result in fiscal year 2026 was softer than expected, with net profit after tax and amortisation declining 7 per cent.
However, the company's outlook appears supported through a combination of cost-outs, marketing initiatives and diminishing headwinds, which are all reinforced by the board's urgency around operational delivery. This provides long term appeal for investors already holding the stock.
Pro Medicus Ltd (ASX: PME)
The team at Fairmont Equities has named this health imaging technology provider's shares as a sell this week.
It believes that the rotation out of technology has not finished, which could mean further declines are on the cards. It said:
The company provides medical imaging software and services to hospitals and healthcare groups across the world. We remain negative on the technology sector as higher interest rates, continuing market volatility and increasing uncertainty leaves investors questioning the high multiples that companies, such as Pro Medicus, trade on. As we saw in the early 2000s, technology stocks can lose a significant amount of value before they become attractive again.
This rotation out of technology stocks often sees investors flocking to hard assets, such as mining company shares. This is what we're seeing in sharemarkets at the moment, and this dynamic has further to go, in my view. PME shares have fallen from $330.48 on July 17, 2025 to trade at $120.17 on April 2, 2026.
QBE Insurance Group Ltd (ASX: QBE)
Over at Investor Pulse, it has named this insurance giant's shares as a buy this week.
It has been pleased with QBE's strong premium rates and higher interest yields. Looking ahead, it appears to believe the positive form can continue. It said:
Elevated premium rates and higher interest yields combine to drive earnings momentum. Improvement was clear in its full year 2025 results released in February. Net profit after tax of $US2.157 billion was up from $US1.779 billion in the prior corresponding period. Premium growth remained solid, with gross written premiums increasing 7 per cent to $US23.9 billion, driven by rate increases across North America and international markets.
At the same time, catastrophe costs were well below expectations. This combination of underwriting strength and cost control supported a 25 per cent increase in the full year dividend to $A1.09 a share. Improved quality of earnings and reduced volatility adds to QBE's appeal.
The post Buy, hold, sell: CSL, QBE, and Pro Medicus shares appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in CSL and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026